Policies regarding Medicare reimbursement for cancer diagnostic.
2025 · 3rd Quarter (July 1 - Sep 30)
PRELUDE CORPORATION (PRELUDEDX)
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Sep 25, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- c16c1e76-89ac-417c-bc78-29c1f719608b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Policies regarding Medicare reimbursement for cancer diagnostic.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.